SG11201806782QA - Promoter - Google Patents
PromoterInfo
- Publication number
- SG11201806782QA SG11201806782QA SG11201806782QA SG11201806782QA SG11201806782QA SG 11201806782Q A SG11201806782Q A SG 11201806782QA SG 11201806782Q A SG11201806782Q A SG 11201806782QA SG 11201806782Q A SG11201806782Q A SG 11201806782QA SG 11201806782Q A SG11201806782Q A SG 11201806782QA
- Authority
- SG
- Singapore
- Prior art keywords
- oxford
- international
- medawar
- pct
- floor
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 abstract 1
- 101150112743 HSPA5 gene Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 241000713880 Spleen focus-forming virus Species 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000035897 transcription Effects 0.000 abstract 1
- 238000013518 transcription Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603577.6A GB201603577D0 (en) | 2016-03-01 | 2016-03-01 | Promoter |
| PCT/GB2017/050537 WO2017149292A1 (en) | 2016-03-01 | 2017-02-28 | Promoter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806782QA true SG11201806782QA (en) | 2018-09-27 |
Family
ID=55807149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806782QA SG11201806782QA (en) | 2016-03-01 | 2017-02-28 | Promoter |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10647999B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3686282B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6960409B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102755545B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017225350B2 (cg-RX-API-DMAC7.html) |
| GB (3) | GB201603577D0 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201806782QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017149292A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110892064A (zh) | 2017-07-25 | 2020-03-17 | 牛津遗传学有限公司 | 腺病毒载体 |
| CN107630035A (zh) * | 2017-09-28 | 2018-01-26 | 兰州大学 | 一种大鼠防御素真核表达载体及其构建方法 |
| GB201800903D0 (en) | 2018-01-19 | 2018-03-07 | Oxford Genetics Ltd | Vectors |
| AU2019215152A1 (en) * | 2018-02-01 | 2020-08-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof |
| GB201901571D0 (en) | 2019-02-05 | 2019-03-27 | Oxford Genetics Ltd | Inducible AAV sysyem |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復pah基因功能的腺相關病毒組成物及其使用方法 |
| JP2024537896A (ja) | 2021-10-18 | 2024-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 |
| AR127674A1 (es) | 2021-10-18 | 2024-02-21 | Regeneron Pharma | Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007081336A1 (en) * | 2006-01-13 | 2007-07-19 | Five Prime Therapeutics, Inc. | Mammalian vectors for high-level expression of recombinant proteins |
| PT1996238T (pt) * | 2006-02-28 | 2016-07-11 | Vaxart Inc | Vetores adenovíricos quiméricos e arncd como agonista de tlr3 |
| WO2008051854A2 (en) * | 2006-10-20 | 2008-05-02 | Trustees Of Boston University | A tunable genetic switch for regulating gene expression |
| EP2097538A4 (en) | 2006-12-07 | 2011-11-30 | Switchgear Genomics | TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS |
| WO2011034950A1 (en) * | 2009-09-16 | 2011-03-24 | Vaxart, Inc. | Immunization strategy to prevent h1n1 infection |
| WO2012112603A1 (en) * | 2011-02-14 | 2012-08-23 | University Of Utah Research Foundations | Constructs and methods for generating induced pluri potent stem ( ips) cells |
| BR112013025819A2 (pt) | 2011-04-07 | 2016-12-20 | Bayer Crospscience N V | promotor específico para semente em algodão |
| EP2771465A1 (en) * | 2011-10-28 | 2014-09-03 | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University | Genetic element that enhances protein translation |
| HUE026516T2 (en) * | 2012-09-24 | 2016-06-28 | Lonza Biologics Plc | Expression vectors containing chimeric cytomegalovirus promoter and enhancer sequences |
| EP3770263A1 (en) | 2013-03-12 | 2021-01-27 | AGC Biologics, Inc. | Improved recombinant protein expression using a hybrid chef1 promoter |
| CN104630267B (zh) * | 2014-07-17 | 2017-10-31 | 清华大学 | 利用tale转录抑制子在哺乳动物细胞中模块化构建合成基因线路的试剂盒 |
| GB201414130D0 (en) * | 2014-08-08 | 2014-09-24 | Agency Science Tech & Res | Mutants of the bacteriophage lambda integrase |
-
2016
- 2016-03-01 GB GBGB1603577.6A patent/GB201603577D0/en not_active Ceased
-
2017
- 2017-02-28 KR KR1020187024944A patent/KR102755545B1/ko active Active
- 2017-02-28 EP EP20157991.9A patent/EP3686282B1/en active Active
- 2017-02-28 US US16/080,765 patent/US10647999B2/en active Active
- 2017-02-28 WO PCT/GB2017/050537 patent/WO2017149292A1/en not_active Ceased
- 2017-02-28 GB GB1703224.4A patent/GB2553170B/en not_active Expired - Fee Related
- 2017-02-28 GB GB2002193.7A patent/GB2578859B/en not_active Expired - Fee Related
- 2017-02-28 JP JP2018545660A patent/JP6960409B2/ja active Active
- 2017-02-28 SG SG11201806782QA patent/SG11201806782QA/en unknown
- 2017-02-28 EP EP17712536.6A patent/EP3423583B1/en active Active
- 2017-02-28 AU AU2017225350A patent/AU2017225350B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB201703224D0 (en) | 2017-04-12 |
| KR102755545B1 (ko) | 2025-01-17 |
| KR20180132045A (ko) | 2018-12-11 |
| AU2017225350B2 (en) | 2023-07-20 |
| GB2553170A (en) | 2018-02-28 |
| CN109072251A (zh) | 2018-12-21 |
| GB2553170B (en) | 2020-05-06 |
| GB202002193D0 (en) | 2020-04-01 |
| JP2019506882A (ja) | 2019-03-14 |
| WO2017149292A1 (en) | 2017-09-08 |
| EP3686282A1 (en) | 2020-07-29 |
| GB2578859A (en) | 2020-05-27 |
| GB2578859B (en) | 2020-10-28 |
| EP3423583B1 (en) | 2023-05-24 |
| US20190071692A1 (en) | 2019-03-07 |
| EP3423583A1 (en) | 2019-01-09 |
| GB201603577D0 (en) | 2016-04-13 |
| JP6960409B2 (ja) | 2021-11-05 |
| US10647999B2 (en) | 2020-05-12 |
| EP3686282B1 (en) | 2024-12-04 |
| AU2017225350A1 (en) | 2018-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201911572YA (en) | Adenoviral vectors | |
| SG11201811244SA (en) | Dual overlapping adeno-associated viral vector system for expressing abc4a | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201805253SA (en) | Compositions and methods related to multimodal therapeutic cell systems for cancer indications | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201909572QA (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
| SG11201808709VA (en) | T cell receptors | |
| SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201907714UA (en) | Adeno-associated virus (aav) clade f vector and uses therefor | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201806542PA (en) | Anti-mica antibodies | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201900573UA (en) | Methods of purifying fc-containing proteins | |
| SG11201808751SA (en) | T cell receptors | |
| SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
| SG11201900038QA (en) | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression |